With open enrollment now underway to sign up for or change their coverage under the Affordable Care Act, oncology nurses and navigators may be hearing questions from cancer patients, survivors, and their family members about navigating this still relatively new insurance marketplace.
With open enrollment now underway to sign up for or change their coverage under the Affordable Care Act, oncology nurses and navigators may be hearing questions from cancer patients, survivors, and their family members about navigating this still relatively new insurance marketplace.
The Cancer Support Community (CSC), along with 18 partnering cancer and patient advocacy organizations, has launched an updated version of the Cancer Insurance Checklist, a resource for people with cancer, a history of cancer, or a risk of cancer to help them evaluate their insurance options.
The Cancer Insurance Checklist guides consumers in reviewing the coverage within each insurance plan they are considering, including coverage for providers, specialists and hospitals, medications, and various common cancer treatments and services they may need. The checklist also provides a worksheet to help the consumer detail the costs associated with each plan. It is designed to be used while evaluating insurance plans and also when discussing them with a navigator or healthcare provider.
Since its launch last fall, the CSC said that the checklist has reached thousands of people impacted by cancer shopping for insurance on the marketplaces. It is available in print and online as a pdf download, in English (www.CancerInsuranceChecklist.org) and in Spanish (http://www.cancerinsurancechecklist.org/es/).
“We want to make sure that people impacted by cancer fully understand the coverage for cancer-related health services under each plan they are considering,” said Kim Thiboldeaux, President and CEO of CSC.
The open enrollment period for 2015 coverage continues until February 15, 2015.
Dual Checkpoint Inhibition Increases Response Rates, Adverse Effects in Melanoma
April 19th 2024Patients with high-risk resectable melanoma treated with ipilimumab plus nivolumab had increased response rates compared with anti-PD1 monotherapy, though it was also associated with increased immune-related adverse effects.
Dual Checkpoint Inhibition Increases Response Rates, Adverse Effects in Melanoma
April 19th 2024Patients with high-risk resectable melanoma treated with ipilimumab plus nivolumab had increased response rates compared with anti-PD1 monotherapy, though it was also associated with increased immune-related adverse effects.
Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit
Cadonilimab Plus Chemo Provides Survival Benefit in Gastric/GEJ Cancer
Lenvatinib Plus Pembrolizumab Improves Survival in Advanced/Recurrent Endometrial Cancer
Frontline Durvalumab Regimen Improves PFS, Responses in Advanced Endometrial Cancer
2 Commerce Drive
Cranbury, NJ 08512